Distribution of events in T-ALL patients according to MRD classification
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total . | ||||
|---|---|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | N . | % . | |
| Total | 75 | 16.2 | 292 | 62.9 | 97 | 20.9 | 464 | — |
| Resistant* | 0 | — | 0 | — | 1 | 1.0 | 1 | 0.2 |
| Relapses | 5 | 6.7 | 51 | 17.5 | 36 | 37.1 | 92 | 19.8 |
| BM | 3 | 4.0 | 23 | 7.9 | 18 | 18.5 | 44 | 9.5 |
| CNS | 2 | 2.7 | 10 | 3.4 | 7 | 7.2 | 19 | 4.1 |
| Testis | 0 | — | 0 | — | 2 | 2.1 | 2 | 0.4 |
| BM + other | 0 | — | 15 | 5.2 | 6 | 6.2 | 21 | 4.5 |
| Other | 0 | — | 3 | 1.0 | 3 | 3.1 | 6 | 1.3 |
| Death in CCR | 1 | 1.3 | 2 | 0.7 | 10 | 10.4 | 13 | 2.8 |
| After chemo | 1 | 1.3 | 2 | 0.7 | 2 | 2.1 | 5 | 1.1 |
| After SCT | 0 | — | 0 | — | 8 | 8.3 | 8 | 1.7 |
| SMN† | 1 | 1.3 | 3 | 1.0 | 1 | 1.0 | 5 | 1.1 |
| CCR | 68 | 90.7 | 236 | 80.8 | 49 | 50.5 | 353 | 76.1 |
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total . | ||||
|---|---|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | N . | % . | |
| Total | 75 | 16.2 | 292 | 62.9 | 97 | 20.9 | 464 | — |
| Resistant* | 0 | — | 0 | — | 1 | 1.0 | 1 | 0.2 |
| Relapses | 5 | 6.7 | 51 | 17.5 | 36 | 37.1 | 92 | 19.8 |
| BM | 3 | 4.0 | 23 | 7.9 | 18 | 18.5 | 44 | 9.5 |
| CNS | 2 | 2.7 | 10 | 3.4 | 7 | 7.2 | 19 | 4.1 |
| Testis | 0 | — | 0 | — | 2 | 2.1 | 2 | 0.4 |
| BM + other | 0 | — | 15 | 5.2 | 6 | 6.2 | 21 | 4.5 |
| Other | 0 | — | 3 | 1.0 | 3 | 3.1 | 6 | 1.3 |
| Death in CCR | 1 | 1.3 | 2 | 0.7 | 10 | 10.4 | 13 | 2.8 |
| After chemo | 1 | 1.3 | 2 | 0.7 | 2 | 2.1 | 5 | 1.1 |
| After SCT | 0 | — | 0 | — | 8 | 8.3 | 8 | 1.7 |
| SMN† | 1 | 1.3 | 3 | 1.0 | 1 | 1.0 | 5 | 1.1 |
| CCR | 68 | 90.7 | 236 | 80.8 | 49 | 50.5 | 353 | 76.1 |
— indicates not applicable; BM, bone marrow; CNS, central nervous system; CCR, complete continuous remission; and SMN, secondary malignant neoplasm.
Only patients alive by TP2 are included in this cohort; consequently, induction deaths in protocol IA and IB are not included.
Resistant patients are those who did not achieve CR by the end of the third HR block of chemotherapy.
Brain tumor (n = 1, MRD-SR, at 7.7 years from diagnosis of T-ALL), myelodysplastic syndrome (n = 1, MRD-IR at 2.1 years), glioblastoma (n = 1, MRD-IR at 4.2 years), mucoepidermoid carcinoma (n = 1, MRD-IR at 2.3 years), and malignant histiocytosis (n = 1, MRD-HR at 1.2 years from diagnosis of T-ALL).